134 related articles for article (PubMed ID: 37882317)
1. CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr virus viremia after transplantation.
Li S; Ge J; Zhou S; Zhu W; Han Y; Chen S; Xue S; Wang Y; Qiu H; Wu X; Wu D
Clin Transl Med; 2023 Oct; 13(10):e1459. PubMed ID: 37882317
[No Abstract] [Full Text] [Related]
2. Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.
Drumheller B; Gebre K; Lockhart B; Margolskee E; Obstfeld A; Paessler M; Pillai V
Int J Lab Hematol; 2022 Aug; 44(4):750-758. PubMed ID: 35419923
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
[TBL] [Abstract][Full Text] [Related]
4. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
Front Immunol; 2021; 12():728962. PubMed ID: 34691036
[TBL] [Abstract][Full Text] [Related]
5. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
[TBL] [Abstract][Full Text] [Related]
6. Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
Liu S; Zhang X; Dai H; Cui W; Yin J; Li Z; Yang X; Yang C; Xue S; Qiu H; Miao M; Chen S; Jin Z; Fu C; Li C; Sun A; Han Y; Wang Y; Yu L; Wu D; Cui Q; Tang X
Blood Cancer J; 2023 Apr; 13(1):60. PubMed ID: 37095120
[TBL] [Abstract][Full Text] [Related]
7. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.
Marks DI; Clifton-Hadley L; Copland M; Hussain J; Menne TF; McMillan A; Moorman AV; Morley N; Okasha D; Patel B; Patrick P; Potter MN; Rowntree CJ; Kirkwood AA; Fielding AK
Lancet Haematol; 2022 Apr; 9(4):e276-e288. PubMed ID: 35358442
[TBL] [Abstract][Full Text] [Related]
8. The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.
Ke P; Zhang X; Liu S; Zhu Q; Ma X; Chen F; Tang X; Han Y; Fu Z; Chen S; Wu D; Qiu H; Zhou J; Bao X
Ann Hematol; 2021 Jul; 100(7):1879-1889. PubMed ID: 33885923
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract][Full Text] [Related]
10. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
Cordoba S; Onuoha S; Thomas S; Pignataro DS; Hough R; Ghorashian S; Vora A; Bonney D; Veys P; Rao K; Lucchini G; Chiesa R; Chu J; Clark L; Fung MM; Smith K; Peticone C; Al-Hajj M; Baldan V; Ferrari M; Srivastava S; Jha R; Arce Vargas F; Duffy K; Day W; Virgo P; Wheeler L; Hancock J; Farzaneh F; Domning S; Zhang Y; Khokhar NZ; Peddareddigari VGR; Wynn R; Pule M; Amrolia PJ
Nat Med; 2021 Oct; 27(10):1797-1805. PubMed ID: 34642489
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-α/β- and CD19-Depleted Grafts.
Laberko A; Bogoyavlenskaya A; Shelikhova L; Shekhovtsova Z; Balashov D; Voronin K; Kurnikova E; Boyakova E; Raykina E; Brilliantova V; Pirumova V; Novichkova G; Maschan A; Maschan M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):483-490. PubMed ID: 28039080
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL.
Qiu Y; Wan CL; Xu MZ; Zhou HX; Liu MJ; Gong WJ; Kang LQ; Sun AN; Yu L; Wu DP; Qian CS; Xue SL
Blood Cancer J; 2023 May; 13(1):66. PubMed ID: 37137904
[No Abstract] [Full Text] [Related]
13. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
[TBL] [Abstract][Full Text] [Related]
14. CD3
Ramanathan S; Lum SH; Nademi Z; Carruthers K; Watson H; Flood T; Owens S; Williams E; Hambleton S; Gennery AR; Slatter M
Transplant Cell Ther; 2023 Aug; 29(8):513.e1-513.e9. PubMed ID: 37279857
[TBL] [Abstract][Full Text] [Related]
15. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
16. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
Pan J; Niu Q; Deng B; Liu S; Wu T; Gao Z; Liu Z; Zhang Y; Qu X; Zhang Y; Liu S; Ling Z; Lin Y; Zhao Y; Song Y; Tan X; Zhang Y; Li Z; Yin Z; Chen B; Yu X; Yan J; Zheng Q; Zhou X; Gao J; Chang AH; Feng X; Tong C
Leukemia; 2019 Dec; 33(12):2854-2866. PubMed ID: 31110217
[TBL] [Abstract][Full Text] [Related]
17. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
[TBL] [Abstract][Full Text] [Related]
18. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma.
Xu H; Lv Q; Huang L; Cao W; Wang J; Meng F; Li C; Zheng M; Chen L; Mu K; Cheng J; Zhu L; Zhou J; Zhang Y; Wang N; Cao Y
Cytotherapy; 2023 Feb; 25(2):185-191. PubMed ID: 36283943
[No Abstract] [Full Text] [Related]
20. Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.
Li Z; Meng F; Li J; Wu T
Front Immunol; 2022; 13():931452. PubMed ID: 35903089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
